Trials / Not Yet Recruiting
Not Yet RecruitingNCT06981988
A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL
A Study to Explore the Dosage and Efficacy of Linperlisib in Combination With Rituximab and to Validate the Efficacy of Linperlisib in Patients With Relapsed/Refractory Indolent NHL
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the reasonable dosage, efficacy and safety of Linperlisib in combination with rituximab in subjects with relapsed/refractory (R/R) indolent non-hodgkin lymphoma(NHL) in adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Linperlisib ； Rituximab | Linperlisib ； Rituximab |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2025-08-01
- Completion
- 2027-02-01
- First posted
- 2025-05-21
- Last updated
- 2025-05-21
Source: ClinicalTrials.gov record NCT06981988. Inclusion in this directory is not an endorsement.